Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of natural antiphosphorylethanolamine antibodies by injection of C-reactive protein.

J M Coll1

  • 1Departamento de Virología, Instituto Nacional de Investigaciones Agrarias, Madrid, Spain.

Immunology Letters
|May 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?

Pathology oncology research : POR·2017
Same author

The amino-terminal domain of ORF149 of koi herpesvirus is preferentially targeted by IgM from carp populations surviving infection.

Archives of virology·2016
Same author

Development of new therapeutical/adjuvant molecules by pepscan mapping of autophagy and IFN inducing determinants of rhabdoviral G proteins.

Molecular immunology·2016
Same author

VHSV G glycoprotein major determinants implicated in triggering the host type I IFN antiviral response as DNA vaccine molecular adjuvants.

Vaccine·2014
Same author

In addition to its antiviral and immunomodulatory properties, the zebrafish β-defensin 2 (zfBD2) is a potent viral DNA vaccine molecular adjuvant.

Antiviral research·2013
Same author

Improving the safety of viral DNA vaccines: development of vectors containing both 5' and 3' homologous regulatory sequences from non-viral origin.

Applied microbiology and biotechnology·2012
Same journal

Impairment of intestinal immunity in gluten-sensitive HLA-DQ8 transgenic mice on a high-fat diet.

Immunology letters·2026
Same journal

Th1 recruitment in atopic dermatitis is due to suppression rather than amplification of Th2.

Immunology letters·2026
Same journal

Interleukin-6: A Potential Link in the Pathophysiology of Restless Legs Syndrome.

Immunology letters·2026
Same journal

The dendritic cell identity crisis: Why do conflicting classifications demand a consensus framework?

Immunology letters·2026
Same journal

The malignancy within: what cancer teaches us about human bonds.

Immunology letters·2026
Same journal

Progranulin enhances complement component 5a-primed neutrophil activation in antineutrophil cytoplasmic antibody-associated vasculitis.

Immunology letters·2026
See all related articles

Goat antibody levels against phosphoryl ethanolamine (anti-PE) decreased after human C-reactive protein (CRP) injection. Conversely, anti-CRP antibody concentrations increased, reaching a plateau by 80 days post-injection.

Area of Science:

  • Immunology
  • Biochemistry

Background:

  • C-reactive protein (CRP) is a key acute-phase protein involved in inflammation.
  • Phosphorylethanolamine (PE) is a phospholipid component of cell membranes.
  • The immune response to self-antigens like CRP and its components is of significant interest.

Purpose of the Study:

  • To investigate the effect of purified human C-reactive protein (CRP) injection on natural antibody levels in goats.
  • To characterize the antibody response to CRP itself.

Main Methods:

  • Goats were injected with purified human C-reactive protein (CRP).
  • Antibody levels, specifically antiphosphorylethanolamine (anti-PE) and anti-CRP, were measured over time.
  • Antibody concentrations were determined using immunoassay techniques.

Related Experiment Videos

Main Results:

  • A decrease in natural antiphosphorylethanolamine (anti-PE) antibody levels was observed following CRP injection.
  • A progressive increase in anti-CRP antibody concentration was detected, starting from undetectable levels.
  • Anti-CRP antibody levels reached a plateau approximately 80 days after the initial CRP injection.

Conclusions:

  • Human CRP injection can modulate natural antibody levels in goats, specifically decreasing anti-PE antibodies.
  • The immune system generates a specific antibody response against human CRP, characterized by a delayed but sustained increase in anti-CRP antibodies.
  • These findings suggest potential cross-reactivity or immune tolerance mechanisms involving CRP and phospholipid antigens.